In its soluble form, DCN has been proposed to prevent lung fibrosis in severe COVID-19 by engaging the receptor of interferon regulatory factors (IRFs), thereby protecting epithelial cells from apoptosis and also neutralizing TGF-β, a strong fibrosis mediator [14,32]. The gene discussed is TGFB1; the disease is COVID-19.